A Randomized, Parallel Group, Open Label, Active Controlled Clinical Study to evaluate the Safety and Efficacy of Safūf-i-Chobchīnī and Ravghan-i-Rāl in the Management of Taqashshur al-Jild (Psoriasis)

The reported prevalence of psoriasis in countries ranges between 0.09%-11.4% making psoriasis a serious global problem. In India the prevalence of psoriasis varies from 0.44-2.8%.The conventional therapy has a good effect but has its own side effects like nausea, hyperpigmentation, pruritis, photo toxicity with serious complications such as skin carcinoma, hepatotoxicity and also worsening of disease. There are several single as well as compound Unani drugs which are in use for centuries for effectively treating taqashshur al-jild but many of them have not been evaluated clinically on scientific parameters. keeping this in view, this Randomized, Parallel Group, Open Label, Active Controlled Clinical Study is designed to evaluate the safety and efficacy of SafÅ«f-i-ChobchÄ«nÄ« and Ravghan-i-Rāl in management of Taqashshur al-Jild(Psoriasis). participants fulfilling inclusion criteria and exclusion criteria will receive either test or control drug as per randomization, in test drug participants will start with SafÅ«f-i-ChobchÄ«nÄ« (orally) and Ravghan-i-Rāl (Topically), in control participants will start with Psoralen(orally) and petroleum jelly(Topically). At baseline,2nd week and last follow up laboratory investigations will be done. Duration of study is 08 weeks.